Zinc Chelator Inhibits Zinc-Induced Islet Amyloid Polypeptide Deposition and Apoptosis in INS-1 Cells
Amyloid deposition and beta cell apoptosis are characteristic pathological features of type 2 diabetes mellitus (DM). Islet amyloid polypeptide (IAPP) is the most abundant component of amyloid deposition. Monomeric IAPP does not form amyloid deposition, but the fibrous IAPP may aggregate and form amyloid deposits. Previous studies have shown that zinc is closely related to IAPP deposition through crosslink with monomeric IAPP into fibrous aggregates. In this study, we aimed to investigate whether chelating zinc could inhibit zinc-induced amyloid deposits and apoptosis of islet beta cell. N, N, N′, N′-Tetrakis (2-pyridylmethyl) ethylenediamine (TPEN) is a specific chelator of zinc, with membrane permeability. It could effectively reduce the concentration of intracellular zinc. So, we used TPEN to treat hIAPP-transfected INS-1 cells. By MTT assay, the concentration (1 μM) and incubation time (12 h) of TPEN without affecting cell viability were determined. The results showed that TPEN reduced zinc-induced IAPP deposition in the culture system. Furthermore, we analyzed the effect of zinc and TPEN on the apoptosis and insulin level. The results showed that TPEN could reverse zinc-induced INS-1 cell apoptosis and insulin secretion. And the anti-apoptosis effects of TPEN is related to extracellular regulated protein kinases (ERK)/c-jun N-terminal kinase (JNK) signaling pathway. The present data indicated that chelating zinc could inhibit zinc-induced amyloid deposition and beta cell apoptosis. Thus, maintaining zinc homeostasis in islet beta cell might become a useful strategy for DM therapy.
KeywordsIslet amyloid polypeptide Zinc Zinc chelator Apoptosis Diabetes mellitus
This study was supported by National Program on Key Basic Research Project (973 Program) (2012CB722405).
Compliance with Ethical Standards
Conflict of interest
The authors declare that they have no conflict of interest.
- 2.Mao Y, Yu L, Mao M, Ma C, Qu L (2018) Design and study of lipopeptide inhibitors on preventing aggregation of human islet amyloid polypeptide residues 11-20. J Pept Sci 24Google Scholar
- 13.Brender JR, Krishnamoorthy J, Sciacca MF, Vivekanandan S, D'Urso L, Chen J, La Rosa C, Ramamoorthy A (2015) Probing the sources of the apparent irreproducibility of amyloid formation: drastic changes in kinetics and a switch in mechanism due to micellelike oligomer formation at critical concentrations of IAPP. J Phys Chem B 119:2886–2896CrossRefGoogle Scholar
- 15.Li LB, Wang ZY (2016) Disruption of brain zinc homeostasis promotes the pathophysiological progress of Alzheimer’s disease. Histol Histopathol 31:623–627Google Scholar
- 23.Rodriguez Camargo DC, Tripsianes K, Buday K, Franko A, Gobl C, Hartlmuller C, Sarkar R, Aichler M, Mettenleiter G, Schulz M, Boddrich A, Erck C, Martens H, Walch AK, Madl T, Wanker EE, Conrad M, de Angelis MH, Reif B (2017) The redox environment triggers conformational changes and aggregation of hIAPP in type II diabetes. Sci Rep 7:44041CrossRefGoogle Scholar
- 29.Lee S, Zheng X, Krishnamoorthy J, Savelieff MG, Park HM, Brender JR, Kim JH, Derrick JS, Kochi A, Lee HJ, Kim C, Ramamoorthy A, Bowers MT, Lim MH (2014) Rational design of a structural framework with potential use to develop chemical reagents that target and modulate multiple facets of Alzheimer’s disease. J Am Chem Soc 136:299–310CrossRefGoogle Scholar